QR-kod

Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study

Abstract Background Zolbetuximab for CLDN18.2-positive advanced gastric cancer frequently causes chemotherapy-induced nausea and vomiting (CINV), particularly during the first infusion. Single-center studies in Japan have reported standardized infusion protocols and antiemetic strategies; however, t...

Full beskrivning

Sparad:
Huvudupphov: Yosuke Ando, Hiroki Banno, Satoe Yamaguchi, Akiko Ban, Kenji Katsuragawa, Ryo Sakurai, Yumiko Sato, Satoshi Nakamura, Toshinori Sasaki, Hirotaka Inoue, Satomi Kumazawa, Takuya Koyama, Saeko Harada, Etsuko Mishima, Hiroshi Matsuoka, Shigeki Yamada, Masayuki Miyazaki
Materialtyp: Artigo
Språk:Inglês
Utgiven: BMC 2026-04-01
Serie:Journal of Pharmaceutical Health Care and Sciences
Ämnen:
Zolbetuximab
CINV
CLDN18.2
Gastric cancer
Länkar:https://doi.org/10.1186/s40780-026-00569-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk